Clinical Trials

Overview

About this study

This initial (pilot) study proposes to follow glycemic control, sleep and activity dynamics of individuals without diabetes identified for initiation of GLP-1 agonists/ GLP-1/GIP agonists from before the start of medication treatment to six months after in an effort to identify the predictors of treatment success. Glycemic control will be monitored using the Ultrahuman M1(UH-M1) continuous glucose monitoring system, while sleep and activity will be measured by the Ultrahuman Ring AIR (UH-RA) on the same user interface. It is proposed that participants will wear the devices for a period of 28 days before the initiation of GLP-1 agonists and up to 12 months post-initiation follow up. A variety of glucose data, heart rate, activity indices will be gathered and tracked through the study period to identify metrics that correlate the most with treatment success.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Participating Mayo Clinic locations

More information